BDTX Insider Kapil Dhingra Buys 40,000 Shares

Kapil Dhingra recently bought 40,000 shares of Black Diamond Therapeutics, Inc. (NasdaqGS: BDTX) on June 26, 2026. This transaction is part of a series of insider purchases at the clinical-stage oncology company.

Insider Buying and Selling at Black Diamond Therapeutics, Inc.

On June 26, 2026, several insiders, including Garry Menzel, Prakash Raman, Ali Behbahani, Kapil Dhingra, Samarth Kulkarni, and Shannon Campbell, each bought 40,000 shares of Black Diamond Therapeutics. None of these transactions were planned under Rule 10b5-1, indicating a direct purchase decision.

Other Institutional Activity in Black Diamond Therapeutics

Institutional investors have been active in Black Diamond Therapeutics as well. T. Rowe Price Investment Management reduced its holdings by 43,496 shares, now holding 10,563,103 shares worth about $22.5 million. NEA Management Company maintained its position with 4,448,757 shares valued at approximately $9.5 million. Acadian Asset Management increased its stake by 718,478 shares, totaling 2,348,651 shares valued at nearly $5 million. Vanguard Capital Management opened a new position with 1,850,468 shares valued at about $3.9 million. Renaissance Technologies boosted its holdings by 694,012 shares, now holding 1,643,747 shares worth $3.5 million.

Black Diamond Therapeutics, Inc. Stock Down 10.7%

Shares of Black Diamond Therapeutics traded near $1.75 on Tuesday. The company has a market cap of approximately $98 million, with a beta of 3.233, suggesting high volatility. The stock's 52-week range is between $1.60 and $4.94. Its 50-day moving average is $2.45, and the 200-day moving average is $2.85. The company maintains a strong current ratio of 8.46 and a quick ratio of 8.14, with a debt-to-equity ratio of 17.15.

Analysts Set New Price Targets

Analysts continue to show confidence in Black Diamond Therapeutics. On April 29, 2026, BTIG maintained its 'buy' rating with an $11 price target. Wedbush also maintained a 'buy' rating on March 17, 2026, with a $14 target. Piper Sandler reiterated its 'buy' rating with an $8 target on January 16, 2026. Overall, the consensus remains positive with a mean target price of about $9.86 based on seven analyst opinions.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts. It focuses on creating therapies for genetically defined tumors, with products like silevertinib in Phase 2 trials for non-small cell lung cancer and glioblastoma. The company is also developing BDTX-4933 and BDTX-4876, targeting various tumor mutations. Founded in 2014, Black Diamond is led by CEO Dr. Mark A. Velleca.

Bottom Line

Kapil Dhingra's recent purchase of Black Diamond Therapeutics shares adds to a trend of insider buying, reflecting confidence in the company's future. While 13F filings and insider transactions are backward-looking, they offer a glimpse into the strategic moves of investors and insiders. Investors often track these activities for potential insights into the company's prospects.